A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system

IntroductionSotorasib and adagrasib have been widely used for the non-small cell lung cancer (NSCLC) patients harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. It's necessary to assess their safety profiles in the real-world population.MethodsA retrospective pharmacovig...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Lisha Wu, Maosheng Xu, Xueqin Li, Dilinuer Aierken, Jinxiu Yu, Tao Qin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	adverse events FAERS disproportionality analysis pharmacovigilance sotorasib adagrasib
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1418469/full